| Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody | |
| Wang, Xi; Zhang, Bo; Chen, Xuelian; Mo, Hongnan; Wu, Dawei; Lan, Bo; Li, Qun; Xu, Binghe; Huang, Jing | |
| 2019 | |
| 卷号 | 10期号:6页码:1395-1401 |
| 关键词 | Esophageal squamous cell carcinoma immune checkpoint inhibitor lactate dehydrogenase markers programmed cell death-1 |
| ISSN号 | 1759-7706 |
| DOI | 10.1111/1759-7714.13083 |
| URL标识 | 查看原文 |
| 收录类别 | SCIE ; PUBMED |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6341918 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Wang, Xi,Zhang, Bo,Chen, Xuelian,et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody[J],2019,10(6):1395-1401. |
| APA | Wang, Xi.,Zhang, Bo.,Chen, Xuelian.,Mo, Hongnan.,Wu, Dawei.,...&Huang, Jing.(2019).Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.,10(6),1395-1401. |
| MLA | Wang, Xi,et al."Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody".10.6(2019):1395-1401. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论